itus develops and acquires patented technologies for the purposes of patent monetization and patent assertion. the company currently has 8 patent portfolios in the areas of key based web conferencing encryption, encrypted cellular communications, nano field emission display (“nfed”), micro electro mechanical systems display (“mems”), j-channel window frame construction, vpn multicast communications, internet telephonic gateway, and enhanced auction technologies. itus’s management team has over 30 years of combined experience in patent monetization and patent assertion, and has generated in excess of $150 million patent licensing revenues
![Anixa Biosciences logo](/files/LOGO/715446-ANIX.png)
Company profile
Ticker
ANIX
Exchange
Website
CEO
Amit Kumar
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
COPYTELE INC, ITUS Corp
SEC CIK
Corporate docs
Subsidiaries
Anixa Diagnostics Corporation • Certainty Therapeutics, Inc. • CopyTele International Ltd. • CopyTele Marketing Inc. • ITUS Patent Acquisition Corporation • J-Channel Industries Corporation • Loyalty Conversion Systems Corporation • Secure Web Conference Corporation • Encrypted Cellular Communications Corporation • Auction Acceleration Corp. ...
IRS number
112622630
ANIX stock data
Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
4 Jun 24
8-K
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
8 May 24
8-K
Submission of Matters to a Vote of Security Holders
22 Mar 24
10-Q
2024 Q1
Quarterly report
12 Mar 24
DEF 14A
Definitive proxy
8 Feb 24
S-8
Registration of securities for employees
16 Jan 24
10-K
2023 FY
Annual report
16 Jan 24
8-K
Regulation FD Disclosure
7 Dec 23
10-Q
2023 Q3
Quarterly report
6 Sep 23
10-Q
2023 Q2
Quarterly report
14 Jun 23
Latest ownership filings
4
Arnold M Baskies
26 Jul 24
4
Lewis H Titterton jr
18 Jun 24
4
Lewis H Titterton jr
14 Jun 24
4
Lewis H Titterton jr
12 Jun 24
4
Lewis H Titterton jr
10 Jun 24
4
Michael Catelani
7 Jun 24
4
AMIT KUMAR
7 Jun 24
SC 13D
Catelani Michael
3 May 24
4
Michael Catelani
2 May 24
4
Lewis H Titterton jr
10 Apr 24
Financial summary
Quarter (USD) | Apr 24 | Jan 24 | Oct 23 | Jul 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Oct 23 | Oct 22 | Oct 21 | Oct 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 995.00 k | 995.00 k | 995.00 k | 995.00 k | 995.00 k | 995.00 k |
Cash burn (monthly) | 1.00 k | 385.42 k | 1.16 mm | 1.08 mm | 485.33 k | 598.25 k |
Cash used (since last report) | 2.90 k | 1.12 mm | 3.35 mm | 3.13 mm | 1.41 mm | 1.73 mm |
Cash remaining | 992.10 k | -122.51 k | -2.36 mm | -2.14 mm | -412.22 k | -739.62 k |
Runway (months of cash) | 992.1 | -0.3 | -2.0 | -2.0 | -0.8 | -1.2 |
Institutional ownership, Q1 2024
2.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 8 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 2.23 bn |
Total shares | 764.73 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Mission Wealth Management | 502.42 k | $1.57 bn |
BK Bank Of New York Mellon | 87.05 k | $271.60 mm |
Cambridge Investment Research Advisors | 41.00 k | $128.00 k |
Gemmer Asset Management | 35.00 k | $109.20 mm |
Raymond James & Associates | 17.76 k | $55.40 mm |
Nations Financial Group Inc, | 15.00 k | $46.80 mm |
Dakota Wealth Management | 15.00 k | $46.80 mm |
International Assets Investment Management | 14.00 k | $46.90 mm |
Simplicity Wealth,LLC | 13.97 k | $43.58 mm |
Westside Investment Management | 13.90 k | $43.37 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Jul 24 | Baskies Arnold M | Common Stock | Buy | Acquire P | No | No | 3.09 | 5,000 | 15.45 k | 115,000 |
14 Jun 24 | Titterton Lewis H jr | Common Stock | Buy | Acquire P | No | No | 2.68 | 4,000 | 10.72 k | 860,612 |
13 Jun 24 | Titterton Lewis H jr | Common Stock | Buy | Acquire P | No | No | 2.7 | 405 | 1.09 k | 856,612 |
11 Jun 24 | Titterton Lewis H jr | Common Stock | Buy | Acquire P | No | No | 2.66 | 7,102 | 18.89 k | 856,207 |
10 Jun 24 | Titterton Lewis H jr | Common Stock | Buy | Acquire P | No | No | 2.6 | 330 | 858.00 | 849,105 |
7 Jun 24 | Kumar Amit | Common Stock | Buy | Acquire P | No | No | 2.41 | 25,000 | 60.25 k | 516,925 |
News
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $7 Price Target
24 Jul 24
EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy
23 Jul 24
EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program
15 Jul 24
HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Lowers Price Target to $7
10 Jun 24
Press releases
Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy
23 Jul 24
Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology
17 Jul 24
Anixa Biosciences Announces $5 Million Share Repurchase Program
15 Jul 24
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
21 May 24
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
8 May 24